POLICYBZR Q2 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹812 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
PB Fintech delivered its first satisfying quarter since listing, driven by exceptional health and term business growth of 53% YoY. The core insurance business showed strong momentum with total premium ARR reaching INR 14,000 crore. Adjusted EBITDA improvement was INR 225 crore over six quarters versus management's conservative guidance of INR 150-200 crore. Renewal Trail ARR grew to INR 436 crore from INR 294 crore, operating at 85% margin—a significant future profit driver. Credit business (Paisabazaar) reached annualized disbursement run-rate of INR 16,500 crore with 600,000 credit cards issued annually, EBITDA positive since December 2022. Q2 PAT loss of INR 21 crore was attributed to health insurance's near-zero first-year margin structure—a deliberate trade-off management celebrates for future renewal value. Management expressed high confidence this will be the last loss-making quarter, targeting first full-year PAT positivity. Key risks include rising NPA concerns in unsecured lending, competitive intensity from PhonePe and others in health insurance, and lumpy brand marketing spend causing quarterly margin volatility.
Colored figures show movement against the previous available record.
Guidance to track
- Management expressed high confidence that Q2 FY24 will be the last loss-making quarter, with Q3 and Q4 historically stronger and on track for full-year profitability.
- The 53% growth in Q2 was described as overperformance; management continues to guide sustainable growth of 30-35% for the protection business going forward.
- Renewal trail provides predictable, high-margin revenue growing from ₹294 crore last year. Management sees this as significant source of profit growth.
- Core business adjusted EBITDA improved by ₹225 crore year-over-year over the past six quarters, exceeding the initial guidance of ₹150-200 crore.
Risks flagged
- As health insurance grows as a percentage of total business, it creates ~1% EBITDA margin compression in the first year due to near-zero contribution margin on first-year premiums, though management views this as positive NPV trade-off.
- Rising NPAs in the sub-₹50K unsecured segment (5% of Paisabazaar's disbursements) could impact lender partner confidence and supply, though management downplays the risk as a smaller segment with partners confident on risk-adjusted returns.
- PhonePe has begun aggressive health insurance advertising during the World Cup. While management expressed confidence that competition hasn't arrived in 15 years, increased marketing spend by well-funded competitors could pressure margins.
- Management acknowledges that POSP growth will be challenged industry-wide as the market matures from ₹20,000 crore, and misinformation in the market could confuse investors about quality players vs. narrative-driven competitors.
Key quotes
- This is the first quarter since we went public that I'm actually happy with the results... Priority zero would be the growth of our health and term business, which accounts for more than three quarters of the value of this company.
- In health, the NPV, when you calculate it, is significantly higher than the first-year revenue because it's a lifetime payout product... Instead of getting a 46% margin as we usually get, on that part you'll be getting a 0% margin. So obviously if that part grows, that will have an impact, but it's a very happy impact.
- I'm extremely confident that this should be our last quarter of losses. So next quarter, we'll definitely have profits.
Research modules